Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Kymera Therapeutics, Inc.
Report date May 26, 2026 · Filed May 27, 2026
Section 16 reporting ended · disclosed 2023-05-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,018 |
Ending reported balance
After 2026-05-27 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-05-26 · Sale · Disposed 3,730 · Balance 57,472 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.99 to $78.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 2 · 2026-05-26 · Sale · Disposed 324 · Balance 57,148 F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person. Row 3 · 2026-05-26 · Sale · Disposed 3,800 · Balance 53,348 F3: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.66 to $79.655, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-05-26 · Sale · Disposed 4,500 · Balance 48,848 F3: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.66 to $80.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-05-26 · Sale · Disposed 551 · Balance 48,297 F3: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.70 to $80.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-05-27 · Sale · Disposed 3,679 · Balance 44,618 F3: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.985 to $81.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-05-27 · Sale · Disposed 600 · Balance 44,018 F3: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.99 to $78.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.66 to $79.655, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.66 to $80.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.70 to $80.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.985 to $81.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 600 | $82.08 | $49,246.02 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 7 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,018 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.99 to $82.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 27, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,679 | $81.50 | $299,849.54 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 6 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,618 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.985 to $81.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 551 | $80.71 | $44,470.22 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,297 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.70 to $80.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 4,500 | $80.02 | $360,110.70 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,848 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.66 to $80.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,800 | $79.39 | $301,690.74 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,348 F3 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.66 to $79.655, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 324 | $79.17 | $25,651.08 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,148 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person. Read SEC document |
| May 26, 2026 Filed May 27, 2026 21:50 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 3,730 | $78.36 | $292,271.24 |
DisclosureSEC source: 0001193125-26-242266 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,472 F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.99 to $78.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0001193125-26-177400 · ownership.xml · derivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,263 Underlying: Common Stock · 200 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F3 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001193125-26-177400 · ownership.xml · derivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,434 Underlying: Common Stock · 100 shares Expires 2035-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 300 | $90.00 | $27,000.00 |
DisclosureSEC source: 0001193125-26-177400 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 200 | $43.50 | $8,700.00 |
DisclosureSEC source: 0001193125-26-177400 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 22, 2026 Filed Apr 24, 2026 20:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 100 | $30.17 | $3,017.00 |
DisclosureSEC source: 0001193125-26-177400 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,300 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · derivative · entry 8 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,463 Underlying: Common Stock · 1,300 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,300 | $90.00 | $117,000.00 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · nonDerivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 15, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 1,300 | $43.50 | $56,550.00 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · nonDerivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,502 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 785 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · derivative · entry 7 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,763 Underlying: Common Stock · 785 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,466 | $0.00 Strike: $30.17 | $0.00 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · derivative · entry 6 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,534 Underlying: Common Stock · 4,466 shares Expires 2035-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F3 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 5,251 | $90.00 | $472,598.40 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 785 | $43.50 | $34,147.50 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,453 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 14, 2026 Filed Apr 16, 2026 22:30 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 4,466 | $30.17 | $134,739.22 |
DisclosureSEC source: 0001193125-26-159538 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,640 | $0.00 Strike: $29.64 | $0.00 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · derivative · entry 7 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,633 Underlying: Common Stock · 14,640 shares Expires 2033-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,100 | $86.05 | $94,655.00 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · nonDerivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 13,540 | $85.41 | $1,156,510.98 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · nonDerivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,302 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.00 to $85.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 14,640 | $29.64 | $433,929.60 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,600 | $0.00 Strike: $29.64 | $0.00 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · derivative · entry 6 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,273 Underlying: Common Stock · 7,600 shares Expires 2033-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 7,600 | $85.38 | $648,881.92 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.02 to $85.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 31, 2026 Filed Apr 1, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 7,600 | $29.64 | $225,264.00 |
DisclosureSEC source: 0001193125-26-138371 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 25, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,727 | $0.00 Strike: $29.64 | $0.00 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · derivative · entry 10 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,873 Underlying: Common Stock · 24,727 shares Expires 2033-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F7 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 25, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 24,727 | $80.26 | $1,984,554.40 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 8 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 25, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 24,727 | $29.64 | $732,908.28 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 7 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 84,400 | $0.00 Strike: $29.64 | $0.00 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · derivative · entry 9 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,600 Underlying: Common Stock · 84,400 shares Expires 2033-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F7 · derivative.exercise_date: Twenty-five percent (25%) of the shares underlying this stock option vested on May 22, 2024 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,200 | $80.05 | $96,060.00 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 6 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,202 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 6,105 | $79.87 | $487,608.79 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,402 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.01 to $80.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 8,214 | $78.40 | $643,950.49 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,507 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.98 to $78.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 52,975 | $77.21 | $4,089,982.55 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,721 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.95 to $77.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 22,756 | $76.73 | $1,746,133.87 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,696 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.96 to $76,94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 23, 2026 Filed Mar 25, 2026 21:15 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 84,400 | $29.64 | $2,501,616.00 |
DisclosureSEC source: 0001193125-26-124367 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 22:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $43.50 | $0.00 |
DisclosureSEC source: 0001193125-26-102630 · ownership.xml · derivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,548 Underlying: Common Stock · 20,000 shares Expires 2034-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F5 · derivative.exercise_date: The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2024, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 22:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 11,111 | $83.72 | $930,207.36 |
DisclosureSEC source: 0001193125-26-102630 · ownership.xml · nonDerivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,052 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.47 to $84.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 22:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 12,882 | $83.10 | $1,070,510.95 |
DisclosureSEC source: 0001193125-26-102630 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,163 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.47 to $83.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 22:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,765 | $82.13 | $144,955.04 |
DisclosureSEC source: 0001193125-26-102630 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,045 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.47 to $82.46, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 11, 2026 Filed Mar 11, 2026 22:51 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | Exercise / conversionCommon Stock | 20,000 | $43.50 | $870,000.00 |
DisclosureSEC source: 0001193125-26-102630 · ownership.xml · nonDerivative · entry 1 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 93,810 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 358 | $86.62 | $31,011.64 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 8 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,810 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.48 to $86.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,150 | $85.78 | $98,647.81 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 7 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,168 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.45 to $86.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 2,017 | $85.04 | $171,518.42 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 6 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,318 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.4475 to $85.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 394 | $84.00 | $33,094.62 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 5 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,335 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.36 to $84.3338, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | GrantStock Option (Right to Buy) · Derivative | 25,150 | $0.00 Strike: $90.10 | $0.00 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · derivative · entry 9 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,150 Underlying: Common Stock · 25,150 shares Expires 2036-03-01 F11 · derivative.exercise_date: The shares underlying this stock option shall vest in forty-eight (48) equal monthly installments following March 2, 2026, subject to the reporting person's continued employment through each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 1,107 | $89.66 | $99,250.74 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 4 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,729 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.17 to $90.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 383 | $88.50 | $33,895.65 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 3 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,836 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.11 to $89.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:00 UTC | Kymera Therapeutics, Inc. KYMR · Entity 3545 | SaleCommon Stock | 549 | $87.75 | $48,175.24 |
DisclosureSEC source: 0001193125-26-091985 · ownership.xml · nonDerivative · entry 2 Chadwick Jeremy G · CIK 0001388406 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,219 F3 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. Such sales were automatic and not in the discretion of the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.11 to $88.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.